Hypoglycemic effects of a beta-agonist, Ro 16-8714, in streptozotocin-diabetic rats: decreased hepatic glucose production and increased glucose utilization in oxidative muscles.
Streptozotocin (STZ)-induced diabetic rats are glycosuric, hyperglycemic, hyperketonemic, overproduce glucose, and have a decreased glucose utilization in oxidative muscles. Treatment with a beta-agonist, Ro 16-8714, decreases the glycosuria, hyperglycemia, hyperketonemia, and hepatic glucose production. Tissue glucose utilization was unchanged, except in oxidative muscles, where it was increased.
Centre de Recherches sur la Nutrition (CNRS), Meudon, France.
P
P
Ferré
L
L
Pénicaud
Y
Y
Hitier
M
M
Meier
J
J
Girard
D015078:2-Hydroxyphenethylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020155:3-Hydroxybutyric Acid; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000378:metabolism*; D006029:Glycosuria; D006885:Hydroxybutyrates / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007700:Kinetics; D007773:Lactates / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D009132:Muscles / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values
D000318:Adrenergic beta-Agonists; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007004:Hypoglycemic Agents; D007773:Lactates; D015078:2-Hydroxyphenethylamine; C045606:4-(3-(bis(beta-hydroxyphenethyl)amino)butyl)benzamide; D005947:Glucose; D020155:3-Hydroxybutyric Acid